Quentin Blackford Joins Paragon 28 Board of Directors

Paragon 28 Inc. has replaced outgoing board member Scott Drake with Quentin Blackford. 

“I am very grateful to Scott for his service to Paragon 28. Scott has been a strong leader and a trusted advisor, and was instrumental in P28’s successful IPO, and seamless transition to a top performing public company,” said Albert DaCosta, CEO and board chairman of Paragon 28.
 
Blackford is serving as chairman of the board’s Compensation Committee and as a member of its Audit Committee. Blackford has more than two decades of senior leadership experience with global medical device companies. He currently serves as president, CEO, and director of iRhythm Technologies.
 
“We are very excited to have Quentin join our Board of Directors,” said DaCosta. “Quentin has one of the most impressive track records in high-growth med-tech, and has led some of the most successful medical device companies of the last decade. I look forward to partnering with Quentin to advance our mission of improving foot and ankle patient outcomes.”
 
Prior to iRhythm Technologies, Blackford worked at Dexcom Inc. from 2017 to 2021, first as chief financial officer (CFO) and then as chief operating officer. Before Dexcom, he worked at Nuvasive Inc. from 2009 to 2017, including as CFO and as head of Strategy and Corporate Integrity from 2014 to 2017. Prior to 2009, Blackford served at Zimmer Biomet Inc. in various senior financial leadership positions. Since October 2017, Blackford has also been a member of Alphatec Holdings Inc.’s Board of Directors, where he serves on the compensation and audit committees.

Blackford is a Certified Public Accountant (inactive) and earned dual bachelor of science degrees in accounting and business administration from Grace College.
 
Based in Englewood, Colo., Paragon 28, is a medical device company exclusively focused on the foot and ankle orthopedic market. Paragon 28 has provided orthopedic solutions, procedural approaches, and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, hallux valgus (bunions), hammertoe, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.